Health
Moderna Pays $950M to Settle COVID Vaccine Patent Fight
Moderna agrees to pay $950 million to settle long-running patent claims with Arbutus and Roivant over lipid nanoparticle technology used in its COVID vaccine.
Key Takeaways
- Moderna pays $950M upfront to settle LNP patent dispute
- Patents cover lipid nanoparticle tech critical to mRNA vaccine delivery
- Settlement removes major legal overhang as Moderna pursues new therapies
DE
DT Editorial AI··via endpoints.news